Description
Rabacfosadine succinate(1431856-99-3), also known as VDC-1101 or GS-9219, is a double prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethl)guanine (PMEG). It is a novel chemotherapy drug approved for the treatment of lymphoma in dogs. Rabacfosadine administered every 3 weeks is usually well tolerated and has shown significant anti-tumour activity in dogs with previously untreated medium and large cell lymphoma.
Uses
Rabacfosadine succinate(1431856-99-3) is used as the acyclic nucleoside phosphonate PMEG double prodrug.
Mechanism of action
Rabacfosadine succinate(1431856-99-3) targets lymphocytes and acts as an anti-tumour agent by inhibiting DNA synthesis through the inhibition of DNA polymerase.
Side effects
The most common adverse reaction to Rabacfosadine succinate is gastrointestinal (anorexia/diarrhoea), which is generally resolved by supportive therapy and/or dose adjustment. Three dogs developed VCOG-CTCAE grade 5 delayed pulmonary fibrosis.
